Agonistic antibodies initiate signalling by the receptors they target, mimicking the activities of native ligands. This Review discusses the clinical successes and failures of agonistic antibodies and explains how recent mechanistic insights should broaden the scope and improve the safety and efficacy of immunotherapies based on these agents.
- Mark S. Cragg
- Xiaojie Yu
- Simon J. Davis